Repurposing of Proton Pump Inhibitors as first identified small molecule inhibitors of endo-β-N-acetylglucosaminidase (ENGase) for the treatment of NGLY1 deficiency, a rare genetic disease.

Bioorganic & Medicinal Chemistry Letters
Yiling BiBalagurunathan Kuberan

Abstract

N-Glycanase deficiency, or NGLY1 deficiency, is an extremely rare human genetic disease. N-Glycanase, encoded by the gene NGLY1, is an important enzyme involved in protein deglycosylation of misfolded proteins. Deglycosylation of misfolded proteins precedes the endoplasmic reticulum (ER)-associated degradation (ERAD) process. NGLY1 patients produce little or no N-glycanase (Ngly1), and the symptoms include global developmental delay, frequent seizures, complex hyperkinetic movement disorder, difficulty in swallowing/aspiration, liver dysfunction, and a lack of tears. Unfortunately, there has not been any therapeutic option available for this rare disease so far. Recently, a proposed molecular mechanism for NGLY1 deficiency suggested that endo-β-N-acetylglucosaminidase (ENGase) inhibitors may be promising therapeutics for NGLY1 patients. Herein, we performed structure-based virtual screening utilizing FDA-approved drug database on this ENGase target to enable repurposing of existing drugs. Several Proton Pump Inhibitors (PPIs), a series of substituted 1H-benzo [d] imidazole, and 1H-imidazo [4,5-b] pyridines, among other scaffolds, have been identified as potent ENGase inhibitors. An electrophoretic mobility shift assay was emplo...Continue Reading

Citations

Jan 13, 2018·Chembiochem : a European Journal of Chemical Biology·Nozomi IshiiIchiro Matsuo
May 8, 2018·G3 : Genes - Genomes - Genetics·Tamy Portillo RodriguezEthan O Perlstein
Apr 27, 2019·Expert Opinion on Drug Discovery·Olivia Slater, Maria Kontoyianni
Mar 7, 2020·Scientific Reports·Susan M WatanabeCarol Carter
May 13, 2020·JIMD Reports·Patrícia Lipari PintoAna Gaspar
Mar 7, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Asuka ShirakawaKoichi Fukase
Jul 6, 2019·European Journal of Medicinal Chemistry·Florence LerouxRebecca Deprez-Poulain
Apr 14, 2018·Journal of Medicinal Chemistry·Yiyue XieJonathan B Baell
Nov 1, 2021·Drug Discovery Today·Vinicius M AlvesAlexander Tropsha

❮ Previous
Next ❯

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.